Literature DB >> 23282971

KSHV/HHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states.

Serge Alexanian1, Jonathan Said, Mark Lones, Sheeja T Pullarkat.   

Abstract

Human herpesvirus-8 (HHV8)-positive effusion-based lymphomas have been termed primary effusion lymphoma (PEL) in the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Kaposi sarcoma herpesvirus (KSHV)/HHV8-negative effusion-based lymphomas (KSHV/HHV8-negative EBLs) resembling PELs have been reported in the literature and in many cases have been (mis)classified as PEL-like lymphomas. Herein, we present a series of cases and a review of KSHV/HHV8-negative EBLs. This lymphoma, although cytomorphologically resembling PEL, is a distinct entity with characteristic clinical and pathologic features. Patients are older, generally human immunodeficiency virus negative and not immunosuppressed, frequently hepatitis C positive compared with the population baseline, and often have an underlying medical condition leading to fluid overload. The lymphoma cells express pan-B-cell antigens in 86.7%, and CD20 is expressed in 71.1% of the cases. The lymphoma is often of germinal center B or mixed germinal center B/activated B-cell signature with the Hans classifier, and Epstein-Barr virus is positive in nearly 30% of cases. Rare T-cell lymphomas were also reported. Clinical outcomes and response to therapy, including isolated aspiration, are relatively favorable compared with cases of PEL. We suggest that HHV8-negative effusion-based lymphoma is a distinct entity associated with fluid overload states.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23282971      PMCID: PMC4104802          DOI: 10.1097/PAS.0b013e318267fabc

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  42 in total

1.  Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course.

Authors:  D Vallisa; R Bertè; A Rocca; G Civardi; F Giangregorio; B Ferrari; G Sbolli; L Cavanna
Journal:  Am J Med       Date:  1999-05       Impact factor: 4.965

2.  Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus.

Authors:  R G Nador; E Cesarman; A Chadburn; D B Dawson; M Q Ansari; J Sald; D M Knowles
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

3.  Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis.

Authors:  Toshitatsu Takao; Yutaka Kobayashi; Junya Kuroda; Atsusi Omoto; Tomoko Nishimura; Yuri Kamitsuji; Etsuko Fukiya; Chie Nakamura; Shinya Kimura; Toshikazu Yoshikawa
Journal:  Am J Hematol       Date:  2004-12       Impact factor: 10.047

Review 4.  Herpes virus type 8-negative primary effusion lymphoma associated with PAX-5 gene rearrangement and hepatitis C virus: a case report and review of the literature.

Authors:  R Ichinohasama; I Miura; N Kobayashi; Y Saitoh; J F DeCoteau; Y Saiki; S Mori; M E Kadin; K Ooya
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

5.  In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype.

Authors:  H Lerat; S Rumin; F Habersetzer; F Berby; M A Trabaud; C Trépo; G Inchauspé
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

6.  Body-cavity-based lymphoma in an HIV-seronegative patient without Kaposi's sarcoma-associated herpesvirus-like DNA sequences.

Authors:  O Hermine; M Michel; A Buzyn-Veil; A Gessain
Journal:  N Engl J Med       Date:  1996-01-25       Impact factor: 91.245

7.  Clonal B-cell expansions in peripheral blood of HCV-infected patients.

Authors:  F Franzin; D G Efremov; G Pozzato; P Tulissi; F Batista; O R Burrone
Journal:  Br J Haematol       Date:  1995-07       Impact factor: 6.998

8.  Human herpes virus-8-negative primary effusion lymphoma in a patient with common variable immunodeficiency.

Authors:  Akiko Hisamoto; Hiromichi Yamane; Akio Hiraki; Yoshinobu Maeda; Nobuharu Fujii; Kenji Sasaki; Toshitugu Miyake; Takashi Sasaki; Tohru Nakamura; Katsuyuki Kiura; Mitsune Tanimoto; Haruhito Kamei
Journal:  Leuk Lymphoma       Date:  2003-11

9.  Human herpes virus 8-negative primary effusion lymphoma (PEL) in a patient after repeated chylous ascites and chylothorax.

Authors:  Atsushi Nonami; Toshihiro Yokoyama; Morishige Takeshita; Koichi Ohshima; Akira Kubota; Seiichi Okamura
Journal:  Intern Med       Date:  2004-03       Impact factor: 1.271

10.  Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions.

Authors:  A Carbone; A Gloghini; E Vaccher; V Zagonel; C Pastore; P Dalla Palma; F Branz; G Saglio; R Volpe; U Tirelli; G Gaidano
Journal:  Br J Haematol       Date:  1996-09       Impact factor: 6.998

View more
  27 in total

Review 1.  Current status of treatment for primary effusion lymphoma.

Authors:  Seiji Okada; Hiroki Goto; Mihoko Yotsumoto
Journal:  Intractable Rare Dis Res       Date:  2014-08

2.  Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma.

Authors:  Matias Mendeville; Margaretha G M Roemer; Mari F C M van den Hout; G Tjitske Los-de Vries; Reno Bladergroen; Phylicia Stathi; Nathalie J Hijmering; Andreas Rosenwald; Bauke Ylstra; Daphne de Jong
Journal:  Blood       Date:  2018-12-03       Impact factor: 22.113

3.  Indolent primary effusion lymphoma-like lymphoma in the pericardium: A case report and review of the literature.

Authors:  Osamu Yamaoka; Toshiki Matsui; Keizo Nishiyama; Akashi Miyamoto; Hiromi Shiota; Chiho Kawahara; Mayumi Shikano; Masatoshi Nagao; Hitoshi Minamiguchi; Shizuki Takemura
Journal:  J Cardiol Cases       Date:  2019-01-23

4.  HHV-8 negative PEL-like lymphoma follicular helper T type in a non-HIV infected elderly.

Authors:  Keisuke Kidoguchi; Masumi Uchino; Emiko Tokushima; Megumi Monji; Fumio Yamasaki; Yasumasa Shimasaki; Koichi Ohshima
Journal:  Ann Hematol       Date:  2020-08-17       Impact factor: 3.673

5.  Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis.

Authors:  Daisuke Kaji; Yasunori Ota; Yasuharu Sato; Koji Nagafuji; Yasunori Ueda; Masataka Okamoto; Yasushi Terasaki; Naoko Tsuyama; Kosei Matsue; Tomohiro Kinoshita; Go Yamamoto; Shuichi Taniguchi; Shigeru Chiba; Koichi Ohshima; Koji Izutsu
Journal:  Blood Adv       Date:  2020-09-22

6.  Primary effusion lymphoma-like lymphoma in a patient with inflammatory bowel disease.

Authors:  Elchanan Nussinson; Fahmi Shibli; Azmi Shahbari; Wasseem Rock; Mazen Elias; Irit Elmalah
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

7.  B-cell lymphomas with discordance between pathological features and clinical behavior.

Authors:  Laurence de Leval; Christiane Copie-Bergman; Andreas Rosenwald; Lisa Rimsza; Stefania Pittaluga; Bettina Bisig; Stefan Dirnhofer; Fabio Facchetti; Stefano Pileri; Falko Fend; Andrew Wotherspoon
Journal:  Virchows Arch       Date:  2017-06-01       Impact factor: 4.064

8.  HHV8/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms: 2015 SH/EAHP Workshop Report-Part 3.

Authors:  Amy Chadburn; Jonathan Said; Dita Gratzinger; John K C Chan; Daphne de Jong; Elaine S Jaffe; Yasodha Natkunam; John R Goodlad
Journal:  Am J Clin Pathol       Date:  2017-02-01       Impact factor: 2.493

Review 9.  Virus-Driven Carcinogenesis.

Authors:  Yuichiro Hatano; Takayasu Ideta; Akihiro Hirata; Kayoko Hatano; Hiroyuki Tomita; Hideshi Okada; Masahito Shimizu; Takuji Tanaka; Akira Hara
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

10.  Primary age-related EBV-associated effusion-based lymphoma successfully treated with rituximab and thoracentesis.

Authors:  Justin J Kuhlman; Muhamad Alhaj Moustafa; Alexander J Tun; David M Menke; Han W Tun; Liuyan Jiang
Journal:  Clin Case Rep       Date:  2021-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.